Introduction
The quinolones are the fastest growing antibacterial class in terms of global revenue, increasingly being used in both the hospital and community sectors to treat a broad range of infections. However, the forthcoming US patent expiry of Bayer's blockbuster Cipro, is set to change the dynamics of this sector while novel compounds are increasingly favored in the light of drug resistance.
Scope
In depth analysis of the fluoroquinolone class as a whole and detailed profiles of leading class members.
Global and regional (US and EU) sales for leading quinolones in 2001 and 2002 are presented along with projections for future performance up to 2008.
Market segmentations by key sites of infection based on extensive expert consultation, are provided for 2002 and 2008.
Report Highlights
Fluoroquinolone sales are expected to remain relatively constant to 2011 (CAGR 2003-2010 = -0.3%). Growth during this period will be driven by increased use of quinolones in the treatment of less severe respiratory tract infections in the community sector and aggressive life-cycle management of Levaquin and Avelox;
The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65% ($3.3 billion) of global sales. The broad spectrum of pathogen activity exhibited by these compounds, alongside their wide range of available formulations, creates significant challenges for companies looking to introduce novel products
Although ciprofloxacin’
Reasons to Purchase
Assess leading fluoroquinolone compounds and identify key success factors within this sector;
Understand the drivers and limits to fluoroquinolone use and predict future performance of these compounds.
Benchmark pipeline fluoroquinolones against currently marketed products and assess future market potential.
TABLE OF CONTENTS
CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into the fluoroquinolone market 3
Fluoroquinolone sales are expected to remain relatively constant to 2011, despite the expiry of US patents for Cipro and Levaquin in 2003 and 2010, respectively (CAGR 2003-2010 = -0.3%). Growth during this period will be driven by increased use in the treatment of less severe respiratory tract infections in the community sector, and aggressive life-cycle management of Levaquin by Johnson and Johnson and Avelox by Bayer 4
Despite the large number and variety of products available, the fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65% ($3.3 billion) of global sales. The broad spectrum of pathogen activity exhibited by these compounds, alongside their wide range of available formulations, creates significant challenges for companies looking to introduce novel products 5
Although ciprofloxacin’
Summary 8
Key metrics 9
Global quinolone sales by quarter, 2001-2002 9
Global quinolone sales forecasts by product, 2003-2011 10
Regional sales of fluoroquinolones, 2002-2008 11
CHAPTER 2 PRODUCT ANALYSES 18
Quinolones overview 18
Fluoroquinolone resistance 20
Key fluoroquinolones 21
Overview 21
Streptococcus pneumoniae activity 25
Activity against tuberculosis 26
Levofloxacin 27
Product overview 27
Licensed indications 28
New indications 29
Related Reports :
Pipeline and Commercial Perspectives:
Commercial Perspectives:
Commercial Insight: Antibacterials - Growth in resistance rates drives niche indications
World Outlook for Antibacterial and Antiseptic Pharmaceuticals 2006-2011
World Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations 2006-2011
For more information kindly visit
http://www.bharatbook.com/
